219 related articles for article (PubMed ID: 32616870)
1. Effects of pirfenidone targeting the tumor microenvironment and tumor-stroma interaction as a novel treatment for non-small cell lung cancer.
Fujiwara A; Funaki S; Fukui E; Kimura K; Kanou T; Ose N; Minami M; Shintani Y
Sci Rep; 2020 Jul; 10(1):10900. PubMed ID: 32616870
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer.
Fujiwara A; Shintani Y; Funaki S; Kawamura T; Kimura T; Minami M; Okumura M
Lung Cancer; 2017 Apr; 106():8-16. PubMed ID: 28285699
[TBL] [Abstract][Full Text] [Related]
3. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy.
Kurita Y; Araya J; Minagawa S; Hara H; Ichikawa A; Saito N; Kadota T; Tsubouchi K; Sato N; Yoshida M; Kobayashi K; Ito S; Fujita Y; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Yoshii Y; Ishikawa T; Numata T; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K
Respir Res; 2017 Jun; 18(1):114. PubMed ID: 28577568
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone promotes the levels of exosomal miR-200 to down-regulate ZEB1 and represses the epithelial-mesenchymal transition of non-small cell lung cancer cells.
Liu J; Cao L; Li Y; Deng P; Pan P; Hu C; Yang H
Hum Cell; 2022 Nov; 35(6):1813-1823. PubMed ID: 36002606
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system.
Krämer M; Markart P; Drakopanagiotakis F; Mamazhakypov A; Schaefer L; Didiasova M; Wygrecka M
Cell Signal; 2020 Jan; 65():109432. PubMed ID: 31693876
[TBL] [Abstract][Full Text] [Related]
7. Pirfenidone inhibits TGF-β1-induced metabolic reprogramming during epithelial-mesenchymal transition in non-small cell lung cancer.
Zhang S; Wang Y; Luo D; Cheng Z; Zeng Q; Wang G; Chen M; Zhang S; Luo P
J Cell Mol Med; 2024 Feb; 28(3):e18059. PubMed ID: 38140828
[TBL] [Abstract][Full Text] [Related]
8. IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling.
Shintani Y; Fujiwara A; Kimura T; Kawamura T; Funaki S; Minami M; Okumura M
J Thorac Oncol; 2016 Sep; 11(9):1482-92. PubMed ID: 27287412
[TBL] [Abstract][Full Text] [Related]
9. Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta.
Aboulkheyr Es H; Zhand S; Thiery JP; Warkiani ME
Integr Biol (Camb); 2020 Jul; 12(7):188-197. PubMed ID: 32638026
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary fibroblasts induce epithelial mesenchymal transition and some characteristics of stem cells in non-small cell lung cancer.
Shintani Y; Abulaiti A; Kimura T; Funaki S; Nakagiri T; Inoue M; Sawabata N; Minami M; Morii E; Okumura M
Ann Thorac Surg; 2013 Aug; 96(2):425-33. PubMed ID: 23773734
[TBL] [Abstract][Full Text] [Related]
11. Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer.
Takatsu F; Suzawa K; Tomida S; Thu YM; Sakaguchi M; Toji T; Ohki M; Tsudaka S; Date K; Matsuda N; Iwata K; Zhu Y; Nakata K; Shien K; Yamamoto H; Nakayama A; Okazaki M; Sugimoto S; Toyooka S
J Mol Med (Berl); 2023 Dec; 101(12):1603-1614. PubMed ID: 37831111
[TBL] [Abstract][Full Text] [Related]
12. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.
Mediavilla-Varela M; Boateng K; Noyes D; Antonia SJ
BMC Cancer; 2016 Mar; 16():176. PubMed ID: 26935219
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3).
Wu C; Lin H; Zhang X
Int Immunopharmacol; 2019 Sep; 74():105700. PubMed ID: 31228816
[TBL] [Abstract][Full Text] [Related]
14. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation.
Vu TN; Chen X; Foda HD; Smaldone GC; Hasaneen NA
Respir Res; 2019 Sep; 20(1):206. PubMed ID: 31511015
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515
[TBL] [Abstract][Full Text] [Related]
16. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer.
Bremnes RM; Dønnem T; Al-Saad S; Al-Shibli K; Andersen S; Sirera R; Camps C; Marinez I; Busund LT
J Thorac Oncol; 2011 Jan; 6(1):209-17. PubMed ID: 21107292
[TBL] [Abstract][Full Text] [Related]
17. Antifibrotic Agent Pirfenidone Suppresses Proliferation of Human Pancreatic Cancer Cells by Inducing G0/G1 Cell Cycle Arrest.
Usugi E; Ishii K; Hirokawa Y; Kanayama K; Matsuda C; Uchida K; Shiraishi T; Watanabe M
Pharmacology; 2019; 103(5-6):250-256. PubMed ID: 30731453
[TBL] [Abstract][Full Text] [Related]
18. Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo.
Li C; Rezov V; Joensuu E; Vartiainen V; Rönty M; Yin M; Myllärniemi M; Koli K
Sci Rep; 2018 Jul; 8(1):10070. PubMed ID: 29968778
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression.
Kanaji N; Yokohira M; Nakano-Narusawa Y; Watanabe N; Imaida K; Kadowaki N; Bandoh S
Respir Res; 2017 Jun; 18(1):118. PubMed ID: 28619066
[TBL] [Abstract][Full Text] [Related]
20. Human lung cancer-associated fibroblasts enhance motility of non-small cell lung cancer cells in co-culture.
Kim SH; Choe C; Shin YS; Jeon MJ; Choi SJ; Lee J; Bae GY; Cha HJ; Kim J
Anticancer Res; 2013 May; 33(5):2001-9. PubMed ID: 23645749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
